Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

140.46USD
19 Sep 2018
Change (% chg)

$-0.08 (-0.06%)
Prev Close
$140.54
Open
$140.76
Day's High
$140.98
Day's Low
$140.06
Volume
1,552,712
Avg. Vol
1,855,391
52-wk High
$148.32
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Janssen Pharmaceutical Says Tremfya Improves Long-Term Patient-Reported Outcomes for Plaque Psoriasis
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Johnson & Johnson ::JANSSEN PHARMACEUTICAL SAYS TREMFYA IMPROVES LONG-TERM PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.JANSSEN SAYS DATA SHOW IMPROVEMENTS IN LONG-TERM OUTCOMES IN PATIENTS SWITCHED TO GUSELKUMAB AFTER INADEQUATE RESPONSE TO TREATMENT WITH ADALIMUMAB.  Full Article

Abbvie Announces Imbruvica Plus Rituximab Approval By U.S. FDA For A Rare Type Of Blood Cancer
Monday, 27 Aug 2018 

Aug 27 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB APPROVAL BY U.S. FDA AS FIRST CHEMOTHERAPY-FREE COMBINATION TREATMENT IN ADULTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA, A RARE TYPE OF BLOOD CANCER.ABBVIE INC - IMBRUVICA NOW HAS A TOTAL OF NINE FDA APPROVALS ACROSS SIX DIFFERENT DISEASES.ABBVIE INC - FDA APPROVED IMBRUVICA (IBRUTINIB) PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH A TYPE OF NON-HODGKIN'S LYMPHOMA.  Full Article

Johnson & Johnson Announces Chris Delorefice As Vice President Of Investor Relations
Wednesday, 8 Aug 2018 

Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES CHRIS DELOREFICE AS VICE PRESIDENT OF INVESTOR RELATIONS.J&J - APPOINTMENT OF CHRIS DELOREFICE TO VICE PRESIDENT OF INVESTOR RELATIONS FOR JOHNSON & JOHNSON, EFFECTIVE AUGUST 13, 2018.  Full Article

CERENOVUS Receives European Regulatory Approval For Bravo Flow Diverter To Treat Intracranial Aneurysms
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - CERENOVUS::CERENOVUS RECEIVES EUROPEAN REGULATORY APPROVAL FOR BRAVO FLOW DIVERTER TO TREAT INTRACRANIAL ANEURYSMS..CERENOVUS SAYS HAS RECEIVED EUROPEAN CE MARK APPROVAL FOR ITS BRAVO FLOW DIVERTER, WHICH IS CURRENTLY NOT APPROVED FOR USE IN UNITED STATES.  Full Article

Johnson & Johnson Consumer Announces Agreement To Acquire Zarbee's Inc
Monday, 30 Jul 2018 

July 30 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON CONSUMER INC. ANNOUNCES AGREEMENT TO ACQUIRE ZARBEE'S, INC., A LEADER IN NATURALLY-BASED HEALTHCARE PRODUCTS.JOHNSON & JOHNSON CONSUMER INC - FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED.JOHNSON & JOHNSON CONSUMER INC - DEAL WILL INCLUDE FULL LINE OF ZARBEE'S NATURALS PRODUCTS.  Full Article

Janssen Receives Positive CHMP Opinion For Darzalex
Friday, 27 Jul 2018 

July 27 (Reuters) - Janssen::JANSSEN RECEIVES POSITIVE CHMP OPINION FOR DARZALEX®▼ (DARATUMUMAB) AS FRONTLINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE.JANSSEN PHARMACEUTICAL COMPANIES- FINAL DECISION REGARDING APPROVAL OF DARATUMUMAB FOR NEWLY DIAGNOSED PATIENTS EXPECTED FROM EC IN COMING MONTHS.  Full Article

Eusa Pharma Acquires Global Rights To J&J's Sylvant For $115 Mln
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Eusa Pharma: :ANNOUNCES ACQUISITION OF GLOBAL RIGHTS TO SYLVANT (SILTUXIMAB) FROM JANSSEN SCIENCES IRELAND UC FOR $115 MILLION.AGREEMENT WITH JANSSEN SCIENCES IRELAND UC TO ACQUIRE GLOBAL RIGHTS TO SYLVANT.  Full Article

Janssen Announces U.S. FDA Approval Of Symtuza
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES U.S. FDA APPROVAL OF SYMTUZA™ (D/C/F/TAF), THE FIRST AND ONLY COMPLETE DARUNAVIR-BASED SINGLE-TABLET REGIMEN FOR THE TREATMENT OF HIV-1 INFECTION.JANSSEN PHARMACEUTICAL COMPANIES SAYS SYMTUZA HAS A BOXED WARNING REGARDING RISK OF POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B.  Full Article

Ligand Pharmaceuticals Says Unit Entered Research & Development Agreement With Janssen Research & Development
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Johnson & Johnson ::LIGAND PHARMACEUTICALS SAYS ON JULY 9, UNIT ENTERED RESEARCH & DEVELOPMENT AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT, LLC - SEC FILING.LIGAND PHARMACEUTICALS - UNIT ENTERED AGREEMENT FOR DEVELOPMENT BY LIGAND OF A HEAVY-CHAIN-ONLY VERSION OF OMNICHICKEN TRANSGENIC CHICKEN PLATFORM.LIGAND PHARMA-JANSSEN MAY REQUEST LIGAND CONDUCT 1 OR MORE HCO OMNICHICKEN IMMUNIZATION CAMPAIGNS WITH JANSSEN RESEARCH & DEVELOPMENT DESIGNATED ANTIGENS.LIGAND PHARMACEUTICALS INC - LIGAND IS ELIGIBLE TO EARN DEFINED MILESTONE PAYMENTS UPON ACHIEVEMENT OF PRE-DETERMINED DELIVERABLES.  Full Article

Saladax Biomedical- Signs License Agreement With Janssen Pharmaceutica
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Saladax Biomedical::SALADAX BIOMEDICAL- SIGNED A LICENSE AGREEMENT WITH JANSSEN PHARMACEUTICA NV.  Full Article

Photo

Exclusive: India, U.S. closing in on package deal to remove trade irritants

NEW DELHI Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said.